Editorial
doi: 10.1093/jnci/94.13.958.Understanding and appreciating overdiagnosis in the PSA era
- PMID:12096074
- DOI: 10.1093/jnci/94.13.958
Item in Clipboard
Editorial
Understanding and appreciating overdiagnosis in the PSA era
Siu-Long Yao et al. J Natl Cancer Inst..
Display options
Format
Display options
Format
No abstract available
Comment on
- Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.Etzioni R, et al.J Natl Cancer Inst. 2002 Jul 3;94(13):981-90. doi: 10.1093/jnci/94.13.981.J Natl Cancer Inst. 2002.PMID:12096083
Similar articles
- Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.Etzioni R, et al.J Natl Cancer Inst. 2002 Jul 3;94(13):981-90. doi: 10.1093/jnci/94.13.981.J Natl Cancer Inst. 2002.PMID:12096083
- A population model of prostate cancer incidence.Tsodikov A, Szabo A, Wegelin J.Tsodikov A, et al.Stat Med. 2006 Aug 30;25(16):2846-66. doi: 10.1002/sim.2257.Stat Med. 2006.PMID:16397859
- Early-stage prostate cancer, PSA screening rates decline.Printz C.Printz C.Cancer. 2016 Mar 15;122(6):825. doi: 10.1002/cncr.29930.Cancer. 2016.PMID:26938268No abstract available.
- Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen.Stephenson RA, Stanford JL.Stephenson RA, et al.World J Urol. 1997;15(6):331-5. doi: 10.1007/BF01300179.World J Urol. 1997.PMID:9436281Review.
- Impact of screening on incidence and mortality of prostate cancer in the United States.Potosky AL, Feuer EJ, Levin DL.Potosky AL, et al.Epidemiol Rev. 2001;23(1):181-6. doi: 10.1093/oxfordjournals.epirev.a000787.Epidemiol Rev. 2001.PMID:11588846Review.
Cited by
- DNA methylation changes in prostate cancer: current developments and future clinical implementation.Hoque MO.Hoque MO.Expert Rev Mol Diagn. 2009 Apr;9(3):243-57. doi: 10.1586/erm.09.10.Expert Rev Mol Diagn. 2009.PMID:19379083Free PMC article.Review.
- Prostate-specific antigen testing among the elderly in community-based family medicine practices.Hudson SV, Ohman-Strickland P, Ferrante JM, Lu-Yao G, Orzano AJ, Crabtree BF.Hudson SV, et al.J Am Board Fam Med. 2009 May-Jun;22(3):257-65. doi: 10.3122/jabfm.2009.03.080136.J Am Board Fam Med. 2009.PMID:19429731Free PMC article.
- Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer.Taylor KL, Hoffman RM, Davis KM, Luta G, Leimpeter A, Lobo T, Kelly SP, Shan J, Aaronson D, Tomko CA, Starosta AJ, Hagerman CJ, Van Den Eeden SK.Taylor KL, et al.Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1240-50. doi: 10.1158/1055-9965.EPI-15-1079. Epub 2016 Jun 2.Cancer Epidemiol Biomarkers Prev. 2016.PMID:27257092Free PMC article.
- The association between patient and disease characteristics, and the risk of disease progression in patients with prostate cancer on active surveillance.Duijn M, de Reijke TM, Barwari K, Hagens MJ, Rynja SP, Immerzeel J, Barentsz JO, Jager A.Duijn M, et al.World J Urol. 2024 Feb 19;42(1):87. doi: 10.1007/s00345-024-04805-9.World J Urol. 2024.PMID:38372786
- Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004.Hussain S, Gunnell D, Donovan J, McPhail S, Hamdy F, Neal D, Albertsen P, Verne J, Stephens P, Trotter C, Martin RM.Hussain S, et al.BJU Int. 2008 Mar;101(5):547-55. doi: 10.1111/j.1464-410X.2007.07338.x. Epub 2008 Jan 10.BJU Int. 2008.PMID:18190630Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous